Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Xandra Owens Breakefield, Ph.D.

Co-Author

This page shows the publications co-authored by Xandra Breakefield and E. Chiocca.
Connection Strength

1.828
  1. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018 03; 4(3):eaar2766.
    View in: PubMed
    Score: 0.193
  2. Tannous et al. Respond. Mol Ther. 2009 Aug; 17(8):1311-1312.
    View in: PubMed
    Score: 0.177
  3. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther. 2003 May 01; 14(7):611-26.
    View in: PubMed
    Score: 0.069
  4. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med. 2003; 76:51-60.
    View in: PubMed
    Score: 0.067
  5. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther. 2001 Apr; 3(4):591-601.
    View in: PubMed
    Score: 0.060
  6. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol. 1999 Dec; 73(12):10426-39.
    View in: PubMed
    Score: 0.054
  7. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999 Aug 15; 59(16):3861-5.
    View in: PubMed
    Score: 0.053
  8. Characterization of single microvesicles in plasma from glioblastoma patients. Neuro Oncol. 2019 05 06; 21(5):606-615.
    View in: PubMed
    Score: 0.052
  9. Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Front Radiat Ther Oncol. 1999; 33:227-40.
    View in: PubMed
    Score: 0.051
  10. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. 1999 Jan-Feb; 6(1):14-20.
    View in: PubMed
    Score: 0.051
  11. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther. 1998 Jun 10; 9(9):1261-73.
    View in: PubMed
    Score: 0.049
  12. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 1998 Jun; 5(6):809-19.
    View in: PubMed
    Score: 0.049
  13. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther. 1998 May-Jun; 5(3):158-62.
    View in: PubMed
    Score: 0.049
  14. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst. 1998 Mar 04; 90(5):370-80.
    View in: PubMed
    Score: 0.048
  15. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 01 22; 20(2):225-235.
    View in: PubMed
    Score: 0.048
  16. Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano. 2018 01 23; 12(1):494-503.
    View in: PubMed
    Score: 0.048
  17. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol. 1998; 451:393-403.
    View in: PubMed
    Score: 0.048
  18. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther. 1997 Nov 20; 8(17):2057-68.
    View in: PubMed
    Score: 0.047
  19. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017 Oct 19; 19(11):1494-1502.
    View in: PubMed
    Score: 0.047
  20. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther. 1996 Oct 20; 7(16):1989-94.
    View in: PubMed
    Score: 0.044
  21. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther. 1996 Oct 20; 7(16):2003-13.
    View in: PubMed
    Score: 0.044
  22. Extracellular Vesicles from High-Grade Glioma Exchange Diverse Pro-oncogenic Signals That Maintain Intratumoral Heterogeneity. Cancer Res. 2016 05 15; 76(10):2876-81.
    View in: PubMed
    Score: 0.042
  23. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther. 1996 Feb 10; 7(3):291-300.
    View in: PubMed
    Score: 0.042
  24. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther. 1995 Dec; 6(12):1543-52.
    View in: PubMed
    Score: 0.041
  25. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther. 1995 Oct; 2(8):531-8.
    View in: PubMed
    Score: 0.041
  26. Gene therapy for brain tumors. Brain Pathol. 1995 Oct; 5(4):345-81.
    View in: PubMed
    Score: 0.041
  27. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995 Oct; 1(10):1171-7.
    View in: PubMed
    Score: 0.041
  28. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994 Nov 15; 54(22):5745-51.
    View in: PubMed
    Score: 0.038
  29. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther. 1994 Sep; 1(5):323-31.
    View in: PubMed
    Score: 0.038
  30. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther. 1994 Aug; 5(8):969-78.
    View in: PubMed
    Score: 0.038
  31. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther. 1994 Feb; 5(2):183-91.
    View in: PubMed
    Score: 0.036
  32. Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol. 1990 Aug; 2(8):739-46.
    View in: PubMed
    Score: 0.029
  33. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001 Apr 01; 61(7):2983-95.
    View in: PubMed
    Score: 0.015
  34. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms. Hum Gene Ther. 1999 Jan 20; 10(2):311-8.
    View in: PubMed
    Score: 0.013
  35. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. 1998 Dec 10; 9(18):2787-94.
    View in: PubMed
    Score: 0.013
  36. Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol. 1995 Dec; 147(6):1840-51.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.